[go: up one dir, main page]

AR094959A1 - Compuestos de imidazo piridina - Google Patents

Compuestos de imidazo piridina

Info

Publication number
AR094959A1
AR094959A1 ARP140100674A ARP140100674A AR094959A1 AR 094959 A1 AR094959 A1 AR 094959A1 AR P140100674 A ARP140100674 A AR P140100674A AR P140100674 A ARP140100674 A AR P140100674A AR 094959 A1 AR094959 A1 AR 094959A1
Authority
AR
Argentina
Prior art keywords
piridine
compounds
imidazo compounds
imidazo
compound
Prior art date
Application number
ARP140100674A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR094959A1 publication Critical patent/AR094959A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epidemiology (AREA)

Abstract

Un compuesto o una sal del mismo farmacéuticamente aceptable. Los compuestos son inhibidores de autotaxina. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque X es un enlace o CH₂; Q es CH₂ u O; L se selecciona a partir del grupo que consiste de -OCH₂ y -CH₂O; o una sal del mismo farmacéuticamente aceptable.
ARP140100674A 2013-03-12 2014-02-28 Compuestos de imidazo piridina AR094959A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361777216P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
AR094959A1 true AR094959A1 (es) 2015-09-09

Family

ID=50382634

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100674A AR094959A1 (es) 2013-03-12 2014-02-28 Compuestos de imidazo piridina

Country Status (15)

Country Link
US (1) US9394317B2 (es)
EP (1) EP2970254B1 (es)
JP (1) JP6163248B2 (es)
KR (1) KR20150119081A (es)
CN (1) CN105143218B (es)
AR (1) AR094959A1 (es)
AU (1) AU2014228355B2 (es)
BR (1) BR112015018509A2 (es)
CA (1) CA2900956C (es)
EA (1) EA201591486A1 (es)
ES (1) ES2639125T3 (es)
MX (1) MX2015012629A (es)
TW (1) TW201520219A (es)
WO (1) WO2014143583A1 (es)
ZA (1) ZA201506747B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI499591B (zh) * 2013-01-11 2015-09-11 Lilly Co Eli 雙環嘧啶化合物
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
CN110526929A (zh) * 2018-05-24 2019-12-03 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
IL284994B2 (en) * 2019-02-01 2024-10-01 Wuhan Humanwell Innovative Drug Res And Development Center Limited Company Pyrrolopyrimidine derivative and use thereof
WO2021088957A1 (zh) * 2019-11-07 2021-05-14 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
KR20220113731A (ko) * 2019-12-11 2022-08-16 스촨 하이스코 파마수티컬 씨오., 엘티디 질소-함유 헤테로사이클릭 오토택신 억제제, 및 이를 함유하는 조성물 및 이의 용도
CN113943295B (zh) * 2020-07-16 2025-08-12 武汉人福创新药物研发中心有限公司 吡咯并嘧啶类化合物及其用途
CN113943296B (zh) * 2020-07-16 2025-07-04 武汉人福创新药物研发中心有限公司 吡咯并嘧啶衍生物及其应用
TWI894325B (zh) * 2020-07-28 2025-08-21 大陸商武漢人福創新藥物研發中心有限公司 含氮雜環化合物的鹽及其鹽的固體形式、藥物組合物和用途
TW202214644A (zh) * 2020-07-28 2022-04-16 大陸商武漢人福創新藥物研發中心有限公司 含氮雜環化合物的固體形式及其藥物組合物和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1071301A (en) * 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
US7524852B2 (en) 2002-06-07 2009-04-28 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
US7465739B2 (en) * 2003-06-10 2008-12-16 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
DE102004020908A1 (de) 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
ES2327240T3 (es) * 2004-12-13 2009-10-27 Solvay Pharmaceuticals Gmbh Nuevos derivados sustituidos de tiofempirimidinona en calidad de inhibidores de 17beta-hidroxiesteroide deshidrogenasa.
ES2407852T3 (es) * 2008-12-01 2013-06-14 Merck Patent Gmbh Pirido[4,3-d]pirimidinas 2,5-diamino sustituidas como inhibidores de autotaxina frente al cáncer
ITRE20090102A1 (it) 2009-10-22 2011-04-23 Cgm Spa Stampo, attrezzatura e metodo per la formatura dietro compressione di oggetti di materiale termoplastico
US9000025B2 (en) * 2010-08-20 2015-04-07 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
EP2714680B1 (en) * 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof

Also Published As

Publication number Publication date
US20150368273A1 (en) 2015-12-24
US9394317B2 (en) 2016-07-19
CA2900956C (en) 2017-11-28
TW201520219A (zh) 2015-06-01
WO2014143583A1 (en) 2014-09-18
EP2970254B1 (en) 2017-06-21
EP2970254A1 (en) 2016-01-20
KR20150119081A (ko) 2015-10-23
ES2639125T3 (es) 2017-10-25
CN105143218A (zh) 2015-12-09
MX2015012629A (es) 2016-07-07
EA201591486A1 (ru) 2016-01-29
BR112015018509A2 (pt) 2017-07-18
AU2014228355A1 (en) 2015-10-01
AU2014228355B2 (en) 2016-02-25
CN105143218B (zh) 2016-12-14
JP2016512254A (ja) 2016-04-25
CA2900956A1 (en) 2014-09-18
JP6163248B2 (ja) 2017-07-12
ZA201506747B (en) 2017-09-27

Similar Documents

Publication Publication Date Title
AR094959A1 (es) Compuestos de imidazo piridina
ES2634490T3 (es) Derivados de ácido napht-2-ylacetico para tratar el sida
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
UA113643C2 (xx) N-цикліламіди як нематоциди
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
MX2016006336A (es) Compuestos pirazolopirimidina.
PE20160862A1 (es) Polimorfo de los inhibidores de la syk
UA117251C2 (uk) 4-членні кільцеві карбоксамідні сполуки, що застосовуються як нематоциди
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
MX2019004626A (es) Compuesto de piridona como inhibidor de c-met.
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
SV2011003997A (es) Pirimidinas fusionadas
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
AR097866A1 (es) Derivados de 4-azaindol
CR20150663A (es) Derivados de diazacarbazol como ligandos de tau para pet
AR095097A1 (es) Compuestos de fenoxietoxi
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
EA201592268A1 (ru) Дигидропиридиноновые ингибиторы mgat2
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
AR091770A1 (es) Indolcarbonitrilos moduladores selectivos de receptores androgenicos
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio
CO2017007940A2 (es) Péptidos antagonistas prgc

Legal Events

Date Code Title Description
FB Suspension of granting procedure